SutroVax Mission

Dedicated to delivering best-in-class conjugate vaccines & novel complex antigen-based vaccines to prevent deadly infectious diseases.

This is Salient

Stop blending in & start leaving your mark on the web

SutroVax

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat

SutroVax

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat

SutroVax

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat

SutroVax

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat

Experience

What real creative freedom feels like in a theme

Pixel Perfection

Salient was built with a high attention to details both in design & code

Platform

Exclusive license to Xpress CFTM, an industrialized cell-free protein synthesis platform, for the vaccine field allowing: (1) Conjugation with unprecedented precision; (2) Rapid production of complex antigens in optimal conformation.

.

People

Assemblage of preeminent vaccinologists, vaccine developers & biotech company-builders joined together to harness the platform to create best-in-class vaccines.

Vaccines

Endeavoring to create best-in-class conjugate vaccines with heightened immunity & broader protection than attainable with current systems.

Well-Financed

Backed by an international syndicate of experienced, blue-chip venture capital & corporate venture investors with an initial $22M Series A financing.

Join Our Team, Change the Shape of Vaccine Research View Open Positions